Effect of beraprost sodium (BPS) in a new rat partial unilateral ureteral obstruction model

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 80, Issue 5-6, 2009, Pages 263-267

  Takenaka, Masahiko ^a   Machida, Noboru ^b   Ida, Nobutaka ^c   Satoh, Nahoko ^c   Kurumatani, Hajimu ^c   Yamane, Yoshihisa ^b  

^a Takenaka Animal Hospital   (Japan)

^b TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^c TORAY INDUSTRIES INC   (Japan)

Author keywords

Beraprost sodium; PGI2; Tubulointerstitial fibrosis; Unilateral ureteral obstruction; UUO

Indexed keywords

BERAPROST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; KIDNEY TUBULE DAMAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DEGENERATION; TREATMENT RESPONSE; URETER FIBROSIS; URETER LIGATION; URETER OBSTRUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; EPOPROSTENOL; FIBROSIS; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES; MALE; RATS; RATS, WISTAR; URETERAL OBSTRUCTION;

ANIMALIA; RATTUS;

EID: 68649086860     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2009.03.002     Document Type: Article

References (33)

1. 2 analogue. Br. J. Pharmacol. 89 (1986) 703-711
2. Bascands J.L., and Schanstra J.P. Obstructive nephropathy: insights from genetically engineered animals. Kidney Int. 68 (2005) 925-937
3. Benfield M.R., McDonald R.A., Bartosh S., Ho P.L., and Harmon W. Changing trends in pediatric transplantation: 2001 Annual Report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr. Transplant. 7 (2003) 321-335
4. 2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency. Prostaglandins Leukot. Essent. Fatty Acids 65 (2001) 223-227
5. Glassock R.J., and Brenner B.M. The major glomerulopathies. In: Braunwald E. (Ed). Harrison's Principles of Internal Medicine. 11th ed (1987) 1176-1183
6. Ii M., Hoshiga M., Fukui R., Negoro N., Nakakoji T., Nishiguchi F., Kohbayashi E., Ishihara T., and Hanafusa T. Beraprost sodium regulates cell cycle in vascular smooth muscle cells through cAMP signaling by preventing down-regulation of p27(Kip1). Cardiovasc. Res. 52 (2001) 500-508
7. Kainoh M., Nishio S., and Nakadate T. Cytoprotective action of beraprost sodium against peroxide-induced damage in vascular endothelial cells. Pharmacology 45 (1992) 61-70
8. Klahr S. Obstructive nephropathy. Kidney Int. 54 (1998) 286-300
9. Klahr S., and Morrissey J. Obstructive nephropathy and renal fibrosis. Am. J. Physiol. Renal Physiol. 283 (2002) F861-F875
10. Koh E., Morimoto S., Jiang B., Inoue T., Nabata T., Kitano S., Yasuda O., Fukuo K., and Ogihara T. Effects of beraprost sodium, a stable analogue of prostacyclin, on hyperplasia, hypertrophy and glycosaminoglycan synthesis of rat aortic smooth muscle cells. Artery 20 (1993) 242-252
11. Kushiro M., Shikata K., Sugimoto H., Shikata Y., Miyatake N., Wada J., Miyasaka M., and Makino H. Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat. Kidney Int. 53 (1998) 1314-1320
12. Mishima K., Baba A., Matsuo M., Itoh Y., and Oishi R. Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity. Free Radic. Biol. Med. 40 (2006) 1564-1577
13. Miyata M., Ueno Y., Sekine H., Ito O., Sakuma F., Koike H., Nishio S., Nishimaki T., and Kasukawa R. Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension. J. Cardiovasc. Pharmacol. 27 (1996) 20-26
14. Nasrallah R., and Hebert R.L. Prostacyclin signaling in the kidney: implications for health and disease. Am. J. Physiol. Renal Physiol. 289 (2005) F235-F246
15. Nasrallah R., Zimpelmann J., Singh S., and Hebert R.L. Molecular and biochemical characterization of prostacyclin receptors in rat kidney. Am. J. Physiol. Renal Physiol. 280 (2001) F266-F277
16. Nath K.A. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am. J. Kidney Dis. 20 (1992) 1-17
17. Nishio S., Matsuura H., Kanai N., Fukatsu Y., Hirano T., Nishikawa N., Kameoka K., and Umetsu T. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn. J. Pharmacol. 47 (1988) 1-10
18. Niwano K., Arai M., Koitabashi N., Hara S., Watanabe A., Sekiguchi K., Tanaka T., Iso T., and Kurabayashi M. Competitive binding of CREB and ATF2 to cAMP/ATF responsive element regulates eNOS gene expression in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1036-1042
19. Ogata Y., Ishidoya S., Fukuzaki A., Kaneto H., Takeda A., Ohyama C., Orikasa S., and Arai Y. Upregulated expression of transforming growth factor-beta, type IV collagen, and plasminogen activator inhibitor-1 mRNA are decreased after release of unilateral ureteral obstruction. Tohoku J. Exp. Med. 197 (2002) 159-168
20. Oida H., Namba T., Sugimoto Y., Ushikubi F., Ohishi H., Ichikawa A., and Narumiya S. In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs. Br. J. Pharmacol. 116 (1995) 2828-2837
21. 2 in incipient diabetic nephropathy. Nephron 92 (2002) 788-796
22. Sim A.K., McCraw A.P., Cleland M.E., Nishio S., and Umetsu T. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation. Arzneimittelforschung 35 (1985) 1816-1818
23. Thornhill B.A., Burt L.E., Chen C., Forbes M.S., and Chevalier R.L. Variable chronic partial ureteral obstruction in the neonatal rat: A new model of ureteropelvic junction obstruction. Kidney Intern. 67 (2005) 42-52
24. Sinik Z., Turan T., Demir S., Yilmaz U., Sert S., and Aybek Z. The effect of partial unilateral ureteral obstruction release and allopurinol on the renal malondialdehyde and glutathione levels. Int. J. Urol. 12 (2005) 990-993
25. Ulm A.H., and Miller F. An operation to produce experimental reversible hydronephrosis in dogs. J. Urol. 88 (1962) 337-341
26. Wen J.G. Partial unilateral ureteral obstruction in rats. Neurourol. Urodyn. 21 (2002) 231-250
27. Wen J.G., Frokiaer J., Jorgensen T.M., and Djurhuus J.C. Obstructive nephropathy: an update of the experimental research. Urol. Res. 27 (1999) 29-39
28. Yamada M., Sasaki R., Sato N., Suzuki M., Tamura M., Matsushita T., and Kurumatani H. Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model. Eur. J. Pharmacol. 449 (2002) 167-176
29. Yamagishi S., Fujimori H., Yonekura H., Yamamoto Y., and Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 41 (1998) 1435-1441
30. Yamashita T., Shikata K., Matsuda M., Okada S., Ogawa D., Sugimoto H., Wada J., and Makino H. Beraprost sodium, prostacyclin analogue, attenuates glomerular hyperfiltration and glomerular macrophage infiltration by modulating ecNOS expression in diabetic rats. Diabetes Res. Clin. Pract. 57 (2002) 149-161
31. Yano T., Itoh Y., Kubota T., Sendo T., Koyama T., Fujita T., Saeki K., Yuo A., and Oishi R. A prostacyclin analog prevents radiocontrast nephropathy via phosphorylation of cyclic AMP response element binding protein. Am. J. Pathol. 166 (2005) 1333-1342
32. Yano T., Itoh Y., Kubota T., Sendo T., and Oishi R. A prostacyclin analog beraprost sodium attenuates radiocontrast media-induced LLC-PK1 cells injury. Kidney Int. 65 (2004) 1654-1663
33. Yokoyama C., Yabuki T., Shimonishi M., Wada M., Hatae T., Ohkawara S., Takeda J., Kinoshita T., Okabe M., and Tanabe T. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 106 (2002) 2397-2403